NCT01325298

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Mercy Center for Corrective Eye Surgery · Academic / Other
• Sex: All
• Age: 14 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate two different ultraviolet (UV) dosing regimens for corneal collagen cross linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.

Conditions

• Keratoconus
• Ectasia
• Corneal Ectasia

Interventions

Type	Name	Description
DEVICE	UV-X Light	UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
DRUG	Riboflavin	Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
DEVICE	UV-X Light	UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
DRUG	Riboflavin	Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.

Timeline

• Start date: 2011-03-01
• Primary completion: 2014-03-01
• Completion: 2014-05-01
• First posted: 2011-03-29
• Last updated: 2011-03-29

Locations

1 site across 1 country: United States